C3 Glomerulopathy: From Early Recognition to Individualized Targeted Therapy

Annenberg Center for Health Sciences
  • 0.0 (0)
  • Medicine

The emergence of novel targeted complement inhibitors has created new opportunities to improve the health outcomes for patients with C3 glomerulopathy (C3G). Andrew Bomback, MD, MPH, discusses the contemporary management of patients with C3G, highlighting the disease burden and complement pathway dysregulation. The safety and efficacy of approved targeted complement inhibitors are reviewed, including the importance of long-term monitoring and associated vaccination strategies. Dr. Bomback also shares his thoughts about providing personalized care by an interprofessional care team.

Episodes

  1. Aug 29

    Optimizing Care

    Treatment goalsSafety of targeted therapyInterprofessional approach

  2. Aug 29

    Targeted Treatments

    Foundational therapyTreatment targetsTargeted therapies: iptacopan, pegcetacoplanBenefits of targeted therapy

  3. Aug 29

    Diagnosis

    Clinical featuresLaboratory assessmentKidney biopsyAdditional assessment

  4. Aug 29

    Pathogenesis

    Classical/Lectin and Alternative pathwaysTriggers

  5. Aug 29

    Burden of Disease

    EpidemiologyPatient story

  • 5 Episodes

About

The emergence of novel targeted complement inhibitors has created new opportunities to improve the health outcomes for patients with C3 glomerulopathy (C3G). Andrew Bomback, MD, MPH, discusses the contemporary management of patients with C3G, highlighting the disease burden and complement pathway dysregulation. The safety and efficacy of approved targeted complement inhibitors are reviewed, including the importance of long-term monitoring and associated vaccination strategies. Dr. Bomback also shares his thoughts about providing personalized care by an interprofessional care team.

Information